SCHEMBL17510201

SCHEMBL17510201

CC(C)(C[O])OCc1nn(Cc2ccccc2)c2ccccc12

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC16A3 O15427 2/20 0.72
CNR1 P21554 3/20 0.50
CNR2 P34972 3/20 0.50
ACHE P22303 2/20 0.50
SCN8A Q9UQD0 1/20 0.45
PDE5A O76074 2/20 0.44
KDM4E B2RXH2 1/20 0.44
GUCY1B2 O75343 1/20 0.44
CYP1A2 P05177 1/20 0.44
CHRM2 P08172 1/20 0.44
HTR1A P08908 1/20 0.44
ADRA2A P08913 1/20 0.44
CYP2D6 P10635 1/20 0.44
CHRM1 P11229 1/20 0.44
DRD1 P21728 1/20 0.44
SLC6A2 P23975 1/20 0.44
SLC6A4 P31645 1/20 0.44
GUCY1A2 P33402 1/20 0.44
ADRA1A P35348 1/20 0.44
OPRM1 P35372 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL927377 0.88 SLC16A3 (0.72) SLC16A3CNR1CNR2ACHESCN8A
SCHEMBL29562615 0.88 SLC16A3 (0.72) SLC16A3CNR1CNR2ACHESCN8A
SCHEMBL22849648 0.87 SLC16A3 (0.75) SLC16A3CNR1CNR2ACHESCN8A
SCHEMBL22850042 0.84 SLC16A3 (0.71) SLC16A3CNR1CNR2ACHESCN8A
Bindarit SCHEMBL187885 0.84 SLC16A3 (1.00) SLC16A3CNR1CNR2ACHESCN8A
Bindarit SCHEMBL29387325 0.84 SLC16A3 (1.00) SLC16A3CNR1CNR2ACHESCN8A
SCHEMBL927988 0.83 SLC16A3 (0.69) SLC16A3CNR1CNR2ACHESCN8A
SCHEMBL15372292 0.83 SLC16A3 (0.84) SLC16A3CNR1CNR2ACHESCN8A
Bindarit SCHEMBL371677 0.83 SLC16A3 (0.98) SLC16A3CNR1CNR2ACHESCN8A
SCHEMBL1650741 0.82 SLC16A3 (0.83) SLC16A3CNR1CNR2ACHESCN8A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2254870-B1 1-BENZYL-3-HYDROXYMETHYLINDAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CX3CR1 ACRAF (IT) 2016-02-24 EP disclosed